Key message {#FPar1}
===========

A multinational epidemiological study on intra-abdominal infection in ICU patients revealed that setting of infection acquisition, anatomical barrier disruption, and severity of disease expression are disease-specific phenotypic characteristics associated with mortality.Antibiotic resistance appeared equally in community-acquired as in hospital-acquired infection.

Introduction {#Sec1}
============

Severe intra-abdominal infections are a frequent and important issue in intensive care (ICU). According to international literature, the abdomen often ranks first or second among the sources of infection or sepsis \[[@CR1]--[@CR3]\].

Intra-abdominal infections pose several particular clinical challenges. First, there is a large span of disease severity ranging from uncomplicated cases to fulminant septic shock and multi-organ dysfunction. Second, there is the broad spectrum of pathogens including Gram-positive and Gram-negative aerobic bacteria, anaerobes, and fungi \[[@CR4]\]. Third, the contribution of microbiological diagnosis is not straightforward as cultures cannot always readily discriminate true pathogens from harmless micro-organisms \[[@CR5], [@CR6]\]. Furthermore, source control encompassing all interventions to eradicate the source of infection, control on-going contamination, and to restore anatomic derangements and physiologic function, is key to clinical management and success, but often difficult to achieve \[[@CR5], [@CR7], [@CR8]\]. Finally, there is the wide variety of clinical entities within intra-abdominal infections. Besides local abscess formation or solid organ infection (e.g., liver abscesses and infected pancreatic necrosis), a classic approach recognizes three types of peritonitis: i.e., primary peritonitis (peritoneal dialysis-related or spontaneous bacterial peritonitis), secondary peritonitis (following anatomical disruption of the GI tract), or tertiary peritonitis (persistent infection despite adequate source control intervention). In addition, cases of intra-abdominal infection are often classified as uncomplicated or complicated. Complicated describes extension of infection from their source into the peritoneal cavity.

Because of this heterogeneity, the intra-abdominal infections are difficult to study \[[@CR9]\]. To bring more clarity in the terminology, an alternative classification for intra-abdominal infections has been proposed \[[@CR10]\]. This system classifies intra-abdominal infections according to their setting of acquisition (community-acquired, healthcare-associated or early onset hospital-acquired, or late-onset hospital-acquired), presence of anatomical disruption (either absent or present resulting in localized or diffuse peritonitis), and severity of disease expression (infection, sepsis, or septic shock). This classification defines different phenotypes of the same disease (e.g., diverticulitis) by covering aspects of (i) the extent of intra-abdominal contamination reflecting the complexity of source control, (ii) level of associated organ failure indicating sense of urgency and prognosis, and (iii) likelihood of antimicrobial resistant micro-organisms or otherwise important pathogens which may require broader antimicrobial coverage (enterococci, *Candida* spp.).

The objective of the study was to describe the epidemiology of intra-abdominal infection in an international cohort of ICU patients and to validate the predictive value for mortality of an alternative classification system.

Methods {#Sec2}
=======

A complete version of the Methods is in Supplement-1. AbSeS was an international, multicenter, prospective observational cohort study conducted between January and December 2016. Consecutive, adult ICU patients diagnosed with intra-abdominal infection, either as primary diagnosis leading to ICU admission or as a complication occurring during the ICU course, were eligible for inclusion. Overall, approval by established national, regional, or local institutional review boards was expedited and granted. The study is registered at ClinicalTrials.gov (number NCT03270345).

Data recorded and definitions {#Sec3}
-----------------------------

We obtained data describing the hospital and intensive-care facility through a center report form. Anonymous patient data were collected through the case report form. Examples of the center and case report forms are in Supplement-2. Type of intra-abdominal infection was defined according to the International Sepsis Forum Consensus Conference Definitions \[[@CR11]\]. Intra-abdominal infections were classified according to setting of infection acquisition, anatomical barrier disruption, and severity of disease expression \[[@CR10]\]. Setting is community-acquired, healthcare-associated and/or early onset hospital-acquired (≤ 7 days of hospital admission), or late-onset hospital-acquired (\> 7 days of hospital admission \[[@CR12]\]). Healthcare-associated onset is defined by at least one of the following risk factors for multidrug-resistant pathogens: nursing home resident, out-of-hospital parenteral nutrition or vascular access, chronic dialysis, recent hospital admission (\< 6 months), or recent antimicrobial therapy (\< 6 months). For convenience sake, 'healthcare-associated and/or early-onset hospital-acquired' cases are designated 'early-onset hospital-acquired'. Intra-abdominal infections were classified as either without anatomical disruption, or with anatomical disruption resulting in localized or diffuse peritonitis (i.e., contamination spread to entire abdominal cavity). Severity of disease expression is defined as either infection, sepsis, or septic shock \[[@CR13]\]. Microbiological assessment was left at the discretion of the physician. Eligible cultures included intra-operative cultures, trans-abdominal fine-needle aspiration, blood cultures presumably related to the intra-abdominal infection, and cultures from abdominal drains sampled ≤ 24 h post-surgery. Thresholds for resistance were those as reported by The European Committee on Antimicrobial Susceptibility Testing (EUCAST) \[[@CR14]\]. Antimicrobial resistance was defined as methicillin resistance for *Staphylococcus aureus*, vancomycin resistance for enterococci, and for Gram-negative bacteria either production of extended-spectrum beta-lactamase (ESBL), carbapenem resistance, or fluoroquinolone resistance (resistance against ciprofloxacin, levofloxacin, or moxifloxacin). To assess relationships between resistance and mortality, we also used the definition of "difficult-to-treat" resistance for Gram-negative bacteria. This combines resistance to all tested carbapenem, beta-lactam, and fluoroquinolone agents, and is associated with worse clinical outcomes in bloodstream infection \[[@CR15], [@CR16]\]. We deviated from this definition, however, using ESBL production as a proxy for resistance against penicillins, cephalosporins, and monobactams. For reporting microbiological results, the number of patients with cultures sampled is used as denominator. Data on anti-infective management included antimicrobial therapy and source control. Antimicrobial coverage of empiric therapy was evaluated for basic coverage (i.e., coverage of Gram-positive, Gram-negative, and anaerobic bacteria), and the association of an antimicrobial agent or initial choice with potential clinical activity against *Pseudomonas aeruginosa*, methicillin-resistant *S. aureus* (MRSA), enterococci, vancomycin-resistant enterococci (VRE), and *Candida*. In this regard, coverage of enterococci targets *Enterococcus faecalis* \[[@CR6]\]. Outcome data included source control assessment 7 days post-diagnosis or earlier if the patient died within that time window. Source control was judged as either successful or having failed. Failure represented either persistent inflammation (clinical evidence of a remaining source of infection) or the necessity of re-intervention following the initial approach (conservative management or source control intervention). Main outcome is ICU mortality with a minimum of 28 days of observation.

Data management and statistical analyses {#Sec4}
----------------------------------------

Simple descriptive statistics were used to characterize the study population; continuous data were summarized by median and interquartile range, categorical data as *n* (%). Logistic regression analysis was used to assess relationships with mortality. Details on the regression models are in Supplement-1. It can be considered inappropriate to include 'source control achievement at day 7' in the model as this covariate is instrumental to the biological pathway between infection onset and mortality. Therefore, we report a logistic regression model with and without source control achievement.

Results {#Sec5}
=======

During the study period, 2850 patients were included; 229 were excluded, because essential data were missing. As such, 2621 patients from 309 ICUs from 42 countries were entered for analysis. Most patients were included in various European regions (*n* = 1830; 69.8%), followed by Middle & South America (*n* = 366; 14.0%), North Africa & Middle-East (*n* = 214; 8.8%), Asia-Pacific (*n* = 174; 6.6%), North America (*n* = 29; 1.1%), and Sub-Saharan Africa (*n* = 8; 0.3%) (Supplement-3).

Characteristics of the study cohort according to setting of infection acquisition are reported in Table [1](#Tab1){ref-type="table"}. Setting of infection acquisition was community-acquired in 828 patients (31.6%), early onset hospital-acquired in 656 patients (25.0%), and late-onset hospital-acquired in 1137 patients (43.4%). Underlying conditions were more frequently observed in cases with healthcare-associated or hospital-acquired infection. Cases with hospital-acquired infection had higher SOFA scores and more often septic shock.Table 1Patient characteristics of intensive-care unit patients with intra-abdominal infection/sepsis according to setting of infection acquisitionCharacteristicTotal cohort (*n* = 2621)Community-acquired (*n* = 828)Early onset hospital-acquired (*n* = 656)Late-onset hospital-acquired (*n* = 1137)*p*\***Demographics**Age, years66 (54--75)67 (52--77)66 (54--77)66 (55--74)0.213Sex, male1488/2615 (56.9)452 (54.6)364 (55.5)672 (59.1)0.133Type of ICU admission2592\*\*799\*\*6561137 Medical472 (18.2)109 (13.7)131 (20.0)232 (20.4)\<0.001 Surgical, non-emergency233 (9.0)19 (2.4)39 (5.9)175 (15.4)\< 0.001 Surgical, emergency1847 (71.3)660 (82.6)478 (72.9)709 (62.4)\< 0.001 Trauma40 (1.5)11 (1.4)8 (1.2)21 (1.8)0.496ICU stay, days9 (4-18)9 (4--18)9 (4--17)10 (5--19)0.183**Underlying conditions\*\*\***Chronic pulmonary disease342 (13.0)96 (11.6)90 (13.7)156 (13.7)0.324AIDS14 (0.5)6 (0.7)3 (0.5)5 (0.4)0.661Malignancy699 (26.7)116 (14.0)170 (25.9)413 (36.3)\< 0.001Neurologic disease165 (6.3)42 (5.1)60 (9.1)75 (6.6)0.008Peptic ulcer disease176 (6.7)57 (6.9)52 (7.9)67 (5.9)0.246Liver disease127 (4.8)24 (1.5)44 (6.7)59 (5.2)0.002Chronic renal failure282 (10.8)57 (6.9)100 (15.2)125 (11.0)\< 0.001Myocardial infarction188 (7.2)48 (5.8)57 (8.7)83 (7.3)0.098Chronic heart failure (NY Heart Association class IV)184 (7.0)36 (4.3)64 (9.8)84 (7.4)\< 0.001Peripheral vascular disease169 (6.4)34 (4.1)48 (7.3)87 (7.7)0.004Diabetes mellitus488 (18.6)116 (14.0)141 (21.5)231 (20.3)\< 0.001Immunosuppression253 (9.7)47 (5.7)83 (12.7)123 (10.8)\< 0.001**Lifestyle risk factors**1363 (52.0)413 (49.9)355 (54.1)595 (52.3)0.257Malnutrition (body mass index \< 20)177 (6.8)46 (5.6)53 (8.1)78 (6.9)0.154Obesity (body mass index ≥ 30)735 (28.0)236 (28.5)197 (30.0)302 (26.6)0.271Tobacco use (\> 20 pack years)446 (17.0)127 (7.1)106 (16.2)213 (18.7)0.113Alcohol abuse (\> 10 g alcohol/day)196 (7.5)59 (7.1)49 (7.5)88 (7.7)0.261IV drug abuse17 (0.6)8 (1.0)3 (0.5)6 (0.5)--**Severity of acute illness**SAPS II score at time of ICU admission49 (39--60)48 (38--59)49 (39--61)49 (38--60)0.183SOFA score at diagnosis6 (3--10)5 (3--9)7 (3--10)6 (3--10)\< 0.001**Severity of disease expression**Infection without sepsis164 (6.3)51 (6.2)42 (6.4)71 (6.2)0.981Sepsis1590 (60.7)528 (63.8)399 (60.8)663 (58.3)0.050Septic shock867 (33.1)249 (30.1)215 (32.8)403 (35.4)0.043**Anatomical disruption**Not present615 (23.5)186 (22.5)166 (25.3)263 (23.1)0.413Yes, with localized peritonitis981 (37.4)342 (41.3)256 (39.0)383 (33.7)0.002Yes, with diffuse peritonitis1025 (39.1)300 (36.2)234 (35.7)491 (43.2)0.001Data are reported as *n* (%) or median (1st--3rd quartile)*SAPS* simplified acute physiology score, *SOFA* sequential organ failure assessment\**p* value indicates differences between patients with community-acquired infection, healthcare-associated infection or early onset hospital-acquired infection, and late-onset hospital-acquired infection\*\*Data missing from 29 patients\*\*\*More details regarding underlying conditions are reported in Supplement--4

The vast majority of cases involved secondary peritonitis (68.4%), followed by biliary tract infection (12.2%), intra-abdominal abscess (6.9%), and pancreatic infection (6.3%). Primary peritonitis, toxic megacolon, peritoneal dialysis-related peritonitis, and typhlitis were less frequent (\< 4%). Details on the distribution according to setting of infection acquisition are reported in Table [2](#Tab2){ref-type="table"}.Table 2Proportion of types of intra-abdominal infection and distribution according to origin of infection acquisitionType of abdominal sepsisTotal *n* (%)\*Community-acquired *n* (%)\*\*Early onset hospital-acquired *n* (%)\*\*Late-onset hospital-acquired *n* (%)\*\*Primary peritonitis103 (3.9)33 (32)28 (27.2)42 (40.8)Secondary and tertiary peritonitis1794 (68.4)588 (32.8)431 (24)775 (43.2)PD-related peritonitis9 (0.3)02 (20)7 (70)Intra-abdominal abscess180 (6.9)36 (20)49 (27.2)95 (52.8)Biliary tract infection319 (12.2)117 (36.7)95 (29.8)107 (33.5)Pancreatic infection165 (6.3)45 (27.3)33 (20)87 (52.7)Typhlitis9 (0.3)03 (33.3)6 (66.6)Toxic megacolon42 (1.6)9 (21.4)15 (35.7)18 (42.9)*PD-related* peritoneal dialysis-related\*% Within column; \*\*% within row

Microbiology {#Sec6}
------------

Microbiological samples were obtained in 1982 patients (75.6%). In 80.4% of these patients, at least one culture was found positive (*n* = 1594). Figure [1](#Fig1){ref-type="fig"} reports the type of samples obtained with their respective proportion of culture positivity. Gram-negative bacteria were most frequently isolated (58.6%) with *Enterobacterales* as predominant family (51.7%) and *Escherichia coli* as most common pathogen (36.8%). Gram-positive aerobic bacteria were isolated in 39.4% of patients with enterococci as most prevalent species (25.9%). Furthermore, anaerobic bacteria and fungi were isolated in 11.7% and 13.0% of patients, respectively. Detailed results on isolated micro-organisms are reported in Table [3](#Tab3){ref-type="table"}. Multidrug-resistant micro-organisms were isolated from 522 patients (26.3%). Antimicrobial resistance rates were not different among community-acquired (26.5%), early onset hospital-acquired (29.0%), and late-onset hospital-acquired infection (24.6%) (*p* = 0.215). There was also no difference in antimicrobial resistance among patients with infection (27.6%), sepsis (26.9%), and septic shock (25.0%) (*p* = 0.449). Antimicrobial resistance is mainly a matter of Gram-negatives, but variations according to geographic region are substantial (Table [4](#Tab4){ref-type="table"}). Regions of particular concern include Eastern- and South-East Europe, North Africa and the Middle-East, and Latin America as \> 35% of patients are infected by at least one antimicrobial resistant micro-organism. Antimicrobial resistance rates according to setting of infection acquisition and region are reported in Supplement-5.Fig. 1Types of microbiological cultures sampled and culture-positive rate in patients with intra-abdominal infectionTable 3Micro-organisms isolated from cultures sampled in patients with intra-abdominal infectionMicro-organismTotal cohort (*n* = 1982)Setting of infection acquisitionCommunity-acquired (*n* = 664)Early onset hospital-acquired (*n* = 482)Late-onset hospital-acquired (*n* = 836)Gram-negative bacteria1161 (58.6)385 (58)287 (59.5)498 (58.5) *Enterobacterales*1024 (51.7)344 (51.8)247 (51.2)433 (51.8)  *Citrobacter sp.*21 (1.1)6 (0.9)8 (1.7)7 (0.8)  *Citrobacter freundii*18 (0.9)6 (0.9)3 (0.6)9 (0.9)  *Escherichia coli*729 (36.8)252 (38)172 (35.7)304 (36.4)  *Enterobacter aerogenes*37 (1.9)15 (2.3)6 (1.2)16 (1.9)  *Enterobacter cloacae*80 (4)31 (4.7)16 (3.3)34 (4.1)  *Hafnia alvei*8 (0.4)3 (0.5)2 (0.4)3 (0.4)  *Morganella morganii*25 (1.3)10 (1.5)5 (1)10 (1.2)  *Klebsiella sp.*51 (2.6)22 (3.3)12 (2.5)17 (2)  *Klebsiella oxytoca\**44 (2.2)23 (3.5)11 (2.3)10 (1.2)  *Klebsiella pneumoniae*170 (8.6)57 (8.6)37 (7.7)76 (9.1)  *Proteus sp.*23 (1.2)9 (1.4)7 (1.5)7 (0.8)  *Proteus mirabilis*63 (3.2)28 (4.2)15 (3.1)20 (2.4)  *Providencia sp.*3 (0.2)01 (0.2)2 (0.2)  *Salmonella enterica*4 (0.2)2 (0.3)2 (0.4)0  *Serratia marcescens*12 (0.6)2 (0.3)4 (0.8)6 (0.7)  *Enterobacterales*, other24 (1.2)7 (1.1)5 (1)12 (1.4) Non-fermenting bacteria233 (11.8)72 (10.8)66 (13.7)95 (11.4)  *Pseudomonas aeruginosa*131 (6.6)41 (6.2)34 (7.1)56 (6.7)  *Pseudomonas sp.* (other or NI)15 (0.8)3 (0.5)4 (0.8)8 (1)  *Stenotrophomonas maltophilia*11 (0.6)5 (0.8)2 (0.4)4 (0.5)  *Acinetobacter baumannii*61 (6.2)18 (2.7)22 (4.6)21 (2.5)  *Acinetobacter sp.* (other or NI)32 (1.6)8 (1.2)12 (2.5)12 (1.4) Other Gram-negative bacteria *Haemophilus influenzae*4 (0.2)2 (0.3)02 (0.2)Gram-positive bacteria781 (39.4)274 (41.3)187 (38.8)320 (38.3) Staphylococci195 (9.8)69 (10.4)44 (9.1)82 (9.8)  *Staphylococcus aureus*64 (3.2)23 (3.5)19 (3.9)22 (2.6)  Coagulase-negative staphylococci100 (5)37 (5.6)23 (4.8)40 (4.8)  Staphylococcus sp. (other or NI)37 (1.9)11 (1.7)5 (1)21 (2.5) Enterococci513 (25.9)173 (26.1)121 (25.1)219 (26.2)  *Enterococcus faecalis*257 (13)83 (12.5)59 (12.2)115 (13.8)  *Enterococcus faecium*216 (10.9)70 (10.5)46 (9.5)100 (12)  *Enterococcus* sp. (other or NI)77 (3.9)33 (5)18 (3.7)26 (3.1) Other Gram-positive bacteria  *Streptococcus* Group A, B, C, G117 (5.9)44 (6.6)27 (5.6)46 (5.5)  *Streptococcus pneumoniae*9 (0.5)4 (0.6)2 (0.4)3 (0.4)  *Streptococcus viridans*33 (1.7)13 (2)7 (1.5)13 (1.6)  *Corynebacterium*8 (0.4)1 (0.2)3 (0.6)4 (0.5)Anaerobe bacteria231 (11.7)83 (12.5)45 (9.3)103 (12.3) *Clostridium perfringens*21 (1.1)7 (1.1)3 (0.6)11 (1.3) *Peptostreptococcus sp.*4 (0.2)1 (0.2)2 (0.4)1 (0.1) *Actinomyces sp.*2 (0.1)1 (0.2)01 (0.1) Gram-positive anaerobe sp. (other or NI)53 (2.7)17 (2.6)12 (2.5)24 (2.9) *Clostridium difficile*8 (0.4)3 (0.5)1 (0.2)4 (0.5) *Bacteroides sp.\**103 (5.2)46 (6.9)17 (3.5)40 (4.8) *Porphyromonas sp.*2 (0.1)02 (0.4)0 *Prevotella sp.*5 (0.3)3 (0.5)02 (0.2) *Fusobacterium sp.*9 (0.5)7 (1.1)02 (0.2) Gram-negative anaerobe sp. (other or NI)66 (3.3)20 (3)13 (2.7)33 (3.9)Fungi258 (13)80 (12)71 (14.7)107 (12.8) *Aspergillus sp.*3 (0.2)02 (0.4)1 (0.1) *Candida sp.*257 (13)81 (12.2)69 (14.3)107 (12.8)  *Candida albicans*173 (8.7)56 (8.4)50 (10.4)67 (8)  *Candida glabrata*35 (1.8)10 (1.5)9 (1.9)16 (1.9)  *Candida krusei*3 (0.2)2 (0.3)01 (0.1)  *Candida parapsilosis*9 (0.5)4 (0.6)1 (0.2)4 (0.5)  *Candida tropicalis*16 (0.8)6 (0.9)2 (0.4)8 (1)  *Candida* sp. (other or NI)20 (1)2 (0.3)7 (1.5)11 (1.3)Table reports *n* patients positive (% of total number of patients with cultures sampled)*NI* not identified\**p* \< 0.05 for differences between setting of infection acquisitionTable 4Rates of antimicrobial resistance in intra-abdominal infections according to geographic regionAntibiotic-resistant pathogenTotal cohort (*n* = 1982)Geographic regionWestern Europe (*n* = 601)Southern Europe (*n* = 558)Eastern and South-East Europe (*n* = 151)Central Europe (*n* = 99)North Africa and Middle-East (*n* = 172)Latin America (*n* = 249)North America (*n* = 22)Asia--Pacific (*n* = 123)Difficult-to-treat resistant Gram-negative bacteria85 (4.3)2 (0.3)38 (6.8)9 (6)015 (8.7)16 (6.4)05 (4.1)Any resistant Gram-negative bacteria\*480 (24.2)54 (9)140 (25.1)59 (39.1)20 (20.2)82 (47.7)90 (36.1)7 (31.8)26 (21.1) ESBL-producing Gram-negative bacteria326 (16.4)37 (6.2)81 (14.5)37 (24.5)9 (9.1)65 (37.8)69 (27.7)7 (31.8)20 (16.3) Carbapenem-resistant Gram-negative bacteria145 (7.3)3 (0.5)61 (10.9)23 (15.2)1 (1)23 (13.4)25 (10)09 (7.3) Fluoroquinolone-resistant Gram-negative bacteria339 (17.1)29 (4.8)108 (19.4)37 (24.5)18 (18.2)57 (33.1)69 (27.7)3 (13.6)17 (13.8)MRSA20 (1)1 (0.2)5 (0.9)5 (3.3)05 (2.9)3 (1.2)01 (0.8)VRE56 (2.8)11 (1.8)15 (2.7)5 (3.3)2 (2)9 (5.2)11 (4.4)1 (4.5)2 (1.6)Antimicrobial resistance\*\* (total)153 (7.7)14 (2.3)57 (10.2)16 (10.6)2 (2)29 (16.9)27 (10.8)1 (4.5)7 (5.7)Antimicrobial resistance\*\*\* (total)522 (26.3)63 (10.5)152 (27.2)65 (43)21 (21.2)87 (50.6)96 (38.6)8 (36.4)28 (22.8)% Represent proportion per column; Resistance rates reflect proportion of patients in which resistant strains are isolated (e.g., *n* MRSA/total *n* patients) and do not represent proportion of resistance within particular pathogens (e.g., *n* MRSA/total *S. aureus* isolates)Denominator for microbiological data includes only patients in which cultures were sampled (data from South Africa are excluded as they included only seven patients)*ESBL* extended-spectrum beta-lactamase-producing, *MRSA* methicillin-resistant *Staphylococcus aureus, VRE* vancomycin-resistant enterococci\*Gram-negative bacteria that are either ESBL-producing, or carbapenem-resistant, or fluoroquinolone-resistant\*\*Total rates of multidrug resistance considering difficult-to-treat resistant Gram-negative bacteria, MRSA, and VRE\*\*\*Total rates of multidrug resistance considering any type of Gram-negative resistance (either ESBL-producing, or carbapenem-resistant, or fluoroquinolone-resistant bacteria), MRSA, and VRE

Antimicrobial therapy {#Sec7}
---------------------

Data on the first-line empiric antimicrobial therapy was available from 2427 patients (92.6%). A basic schedule covering aerobic Gram-positive, Gram-negative, and anaerobic bacteria was prescribed in 2291 patients (94.4%). An anti-pseudomonal agent was prescribed in 1978 patients (81.8%). Empiric coverage of MRSA and VRE was added in, respectively, 647 patients (26.7%) and 140 patients (5.8%). An antifungal agent was associated in 436 patients (18%). In 365 patients, two agents with anti-anaerobic activity were prescribed (15%). Double anti-anaerobic coverage was more frequently prescribed in hospital-acquired cases (18.2%) compared with community-acquired cases (14.2%). No other differences in antimicrobial coverage according to setting of infection acquisition were observed (Supplement-6).

Source control {#Sec8}
--------------

Data on the initial approach to control the infection are reported in 2438 patients. A source control intervention was carried out in 2334 patients (95.7%), and included drainage (94.0%), decompressive surgery (7.9%), and restoration of anatomy and function (28.2%). Among patients undergoing source control, persistent inflammation at day 7 was reported in 692 patients (29.6%). An additional intervention was deemed necessary in 382 patients (16.4%). Among patients with an initial conservative approach (*n* = 104), 30 patients experienced persistent inflammation (28.8%), and a source control intervention was performed in 5 patients (4.8%). More details on source control interventions and evaluations are summarized in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Initial approach to control the source of infection. Several types of source control interventions could have been executed in a single patient

Mortality {#Sec9}
---------

Overall mortality was 29.1% (752/2588). Univariate relationships with mortality are reported in Supplement-7. Mortality stepwise increased with ascending SOFA scores (Supplement-8). Achievement of source control at day 7 was associated with lower mortality (248/1438, 17.2%) compared with cases with persistent inflammation (367/761, 51.8%) and those requiring surgical revision (110/389, 28.3%) (*p* \< 0.001). We reported mortality according to setting of infection acquisition, anatomical disruption, and severity of disease expression. Mortality was 23.7% in community-acquired cases, 27.3% in early onset hospital-acquired cases, and 33.9% in late-onset hospital-acquired cases (*p* \< 0.001). Regarding anatomical disruption, no difference in mortality was observed between patients without anatomical disruption and those with localized peritonitis (respectively, 25.0% and 24.2%, *p* = 0.135). Mortality in patients with diffuse peritonitis (36.0%) was higher compared with the former categories (*p* \< 0.001). Finally, mortality stepwise increased with greater severity of disease expression: 12.8% in infected patients without sepsis, 24.5% in septic patients, and 40.3% in patients with septic shock (*p* \< 0.001). Table [5](#Tab5){ref-type="table"} reports mortality rates for all different phenotypes of intra-abdominal infection according to setting of infection acquisition, anatomical disruption, and severity of disease expression. The grid describes a stepwise increase in mortality along with combinations including septic shock, diffuse peritonitis, and late-onset hospital-acquired infection.Table 5Mortality according to alternative classification of intra-abdominal infectionSeverity of disease expressionSetting of infection acquisitionCommunity-acquiredEarly onset hospital-acquiredLate-onset hospital-acquired Septic shock18/6428.1%25/8330.1%48/10147.5%21/6333.3%13/6121.3%37/9140.7%45/10343.7%48/11043.6%94/19049.5% Sepsis13/11611.2%42/22119%37/17421.3%27/9030%33/17019.4%43/12833.6%26/14717.7%62/23726.2%99/27536% Infection1/714.3%3/2213.6%4/2218.2%0/70%0/210%2/1414.3%1/128.3%8/3622.2%2/238.7%NoYes, with localized peritonitisYes, with diffuse peritonitisNoYes, with localized peritonitisYes, with diffuse peritonitisNoYes, with localized peritonitisYes, with diffuse peritonitisAnatomical disruptionAnatomical disruptionAnatomical disruption

Logistic regression analysis identified late-onset hospital-acquired infection, diffuse peritonitis, sepsis and septic shock, older age, malnutrition, diabetes mellitus, liver failure, and congestive heart failure as independent risk factors for death (Table [6](#Tab6){ref-type="table"}). The association of an anti-MRSA agent in the empiric antimicrobial scheme was associated with decreased risk of death. Antimicrobial resistance defined as MRSA, VRE, or difficult-to-treat resistant Gram-negatives did not reached the final models. However, when antimicrobial resistance in Gram-negative bacteria was defined as either ESBL production or carbapenem resistance, this covariate became significantly associated with mortality (Supplement-9).Table 6Independent relationships with mortality in critically ill patients with intra-abdominal infectionVariableModel with source control achievement\*\
OR (95% CI)Model without source control achievement\*\*\
OR (95% CI)Setting of infection acquisition Community-acquired infectionReferenceReference Early onset hospital-acquired infection (≤ 7 days)1.15 (0.84--1.58)1.18 (0.88--1.59) Late-onset hospital-acquired infection (\> 7 days)1.76 (1.34--2.32)1.76 (1.36--2.30)Anatomical disruption No anatomical barrier disruptionReferenceReference Anatomical disruption with localized peritonitis1.28 (0.95--1.75)1.26 (0.95--1.69) Anatomical disruption with diffuse peritonitis1.99 (1.49--2.67)2.04 (1.55--2.70)Severity of disease expression InfectionReferenceReference Sepsis2.44 (1.37--4.66)2.28 (1.31--4.28) Septic shock5.22 (2.91--10)4.93 (2.80--9.30)Age (per year increase)1.03 (1.02--1.04)1.03 (1.03--1.04)Underlying conditions Malnutrition (body mass index \< 20)2.07 (1.34--3.17)2.15 (1.43--3.21) Diabetes mellitus1.31 (0.99--1.73)1.32 (1.01--1.72) Liver failure2.03 (1.23--3.33)2.50 (1.55--4.02) Congestive heart failure1.86 (1.24--2.81)1.92 (1.31--2.81)Empiric antimicrobial coverage Anti-MRSA agent0.77 (0.59--1)0.77 (0.59--0.98) Double anaerobe coverage--1.28 (0.97--1.71)Source control achievement at day 7 SuccessReference-- Failure, persistent signs of inflammation4.85 (3.79--6.22)-- Failure, additional intervention required following initial approach1.93 (1.41--2.65)--The variable "antimicrobial resistance" defined as either MRSA, vancomycin-resistant enterococci (VRE), or difficult-to-treat resistant Gram-negative bacteria did not achieve the final regression model. Supplement-9 reports the results of the logistic regression models with antibiotic resistance defined as either MRSA, VRE, ESBL-producing, or carbapenem-resistant Gram-negative bacteria. In these logistic regression models, antibiotic resistance was associated with increased risk of mortality, while other covariates remained stable*OR* odds ratio, *CI* confidence interval, *MRSA* methicillin-resistant *Staphylococcus aureus*\*Area under the receiver-operating curve characteristic: 0.778; \*\*Area under the receiver-operating curve characteristic: 0.689

Discussion {#Sec10}
==========

This multicenter observational study provided epidemiological insights in critically ill patients with intra-abdominal infection. The multicentre input of sequential cases of intra-abdominal infection offers a global view of the case mix of different presentations of intra-abdominal infection requiring ICU admission or occurring within the framework of an ICU stay. In spite of clinical heterogeneity, the core characteristics of intra-abdominal infection are quite generic including anatomical disruption and polymicrobial infection. Because of the broad variety in intra-abdominal infections, data were described according to a new classification based on setting of acquisition, presence of anatomical disruption, and severity of disease. Irrespective of type of intra-abdominal infection, mortality was higher in late-onset hospital-acquired cases with diffuse peritonitis and septic shock. This classification allows comparison across a spectrum of intra-abdominal infections and might be used for including patients in future clinical trials.

There were no differences in the prevalence of antimicrobial resistance in microbiological cultures sampled in community-acquired vs. early onset vs. late-onset hospital-acquired infection. This may be explained at least in part by the spread of resistance clones/genes into the community, as is the case for ESBL-producing or carbapenem-resistant *Enterobacterales* (formerly known as *Enterobacteriaceae*). This is certainly the case for risk regions such as Eastern and South-East Europe, the Middle-East, and Latin America, and matches with the results of a global point prevalence study on antimicrobial consumption and resistance \[[@CR17]\]. This confirms the trend that classic risk factors for antimicrobial resistance involvement are losing predictive value as illustrated in a multicenter study reporting antimicrobial resistance in 39% of infections in patients without an obvious risk profile as evidenced by prior antibiotic exposure and/or hospitalisation \[[@CR18]\]. This observation is highly relevant as it might stress the need for last-line antimicrobial therapy in community-acquired infection in selected regions. Considering local ecology together with the individual patient profile, and disease severity remains essential. However, antimicrobial resistance in key-pathogens isolated in intra-abdominal infection does not seem to be associated with increased virulence, as it occurred at similar rates in infection, sepsis, and septic shock. Overall prevalence of enterococci was 26% and thereby substantially higher as previously reported \[[@CR19]--[@CR22]\]. This trend can be attributed to the steadily emergence of enterococci in acute care settings or to the particular composition of a cohort of exclusively critically ill patients \[[@CR23]\].

No differences in empiric antibacterial regimens were observed according to setting of infection acquisition. Anti-pseudomonal coverage was provided up-front in not only late-onset cases, a supposed classic risk factor for antimicrobial resistant infection, including *P. aeruginosa* strains, but also in community-acquired or early onset hospital-acquired infections. This is probably triggered by a safety-reflex in physicians, not to miss any potential pathogen, especially *P. aeruginosa* strains. Thus, the risk factor-based antibiotic strategy that appears in all guidelines seems not to be implemented in a large real-life sample of intra-abdominal infection in the ICU, reflecting response to severity.

It is reassuring that the vast majority of intra-abdominal infections in the ICU were approached by an early source control intervention. It has been established that surgery needs to be performed after hemodynamic stabilization, but nevertheless should be performed as early as possible aiming at damage control \[[@CR24]\]. The importance of source is evidenced by the increased mortality among patients with persistent inflammation or need for additional surgical intervention.

Late-onset hospital-acquired infection, diffuse peritonitis, and septic shock were identified as independent risk factors for mortality, and confirm the robustness of the new classification system for risk stratification. Antimicrobial resistance defined as either MRSA, VRE, ESBL-producing, or carbapenem-resistant Gram-negative bacteria was independently associated with increased mortality (Supplement-9). Surprisingly, however, the more strict definition of either MRSA, VRE, or difficult-to-treat resistant Gram-negative bacteria was not associated with increased mortality. Probably, the cohort lacked sufficient power as in only 85 patients, difficult-to-treat Gram-negatives were involved *vs*. 341 ESBL-producing or carbapenem-resistant Gram-negative bacteria. We have no explanation for the favorable association with anti-MRSA agents. This can hardly be due to the anti-MRSA activity as such, since MRSA was isolated in only 20 patients. The advantageous association might be due to the anti-enterococcal activity of these agents. Yet, enterococcal coverage as such (not necessarily covering MRSA) was not retained in the final regression model assessing relationships with mortality. Hence, this observation might just be an incidental finding. On the other hand, the absence of an association between empiric antifungal therapy and outcome seems consistent with the finding of other cohort studies and randomized-controlled trials that did not demonstrate the effect of empirical *Candida* coverage and favorable outcome \[[@CR25], [@CR26]\].

This study has limitations. This is an observational cohort study disposed to confounding. Some geographic regions are poorly represented obstructing conclusive results. Evaluation of source control achievement remains a subjective appreciation performed by the attending physician; given the study scale, it was not feasible to establish an independent panel for in-depth evaluation of source control as previously reported \[[@CR27]\]. At the same line, given the observational study design, there was no predefined approach to source control \[[@CR7]\]. In addition, with this paper, we intended to provide a general epidemiological snapshot. Therefore, detailed country-specific or disease-specific analyses fell outside the scope of this report. Finally, we could not report the proportion of ICU patients with intra-abdominal infection/sepsis as the total number of admissions during the inclusion of cases was not recorded.

In conclusion, this multinational cohort of ICU patients with intra-abdominal infection revealed that late-onset healthcare-associated infection, diffuse peritonitis, and sepsis or septic shock are independent risk factors for mortality. Therefore, setting of infection acquisition, anatomical disruption, and severity of disease expression are disease-specific phenotypic characteristics associated with outcome, irrespective of the type of intra-abdominal infection. Antimicrobial resistance is mainly an issue of Gram-negatives and a particular concern in specific geographic areas and associated with worse outcome as was failure of source control.
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